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Abstract
A pilot study was conducted to assess the efficacy and feasibility of daily low-dose cis-
platin with concurrent thoracic irradiation for clinically unresectable non-small-cell lung cancer
(NSCLC). Patients with inoperable NSCLC who had poor risk factors such as advanced age, poor
performance status, poor lung function, or concomitant active malignancy were entered into the
study. Low-dose cisplatin (6 mg/m2) was administered daily before concurrent thoracic irradiation
(2 Gy/day; total dose of 60 Gy) was given. Twenty-five patients were registered. The majority of
the patients had either stage IIIA (24.0%) or stage IIIB (60.0%) disease. Fifteen patients (60.0%)
completed the planned treatment. Both chemotherapy and radiotherapy were stopped in 3 patients
(12.0%) due to poor response, and 7 patients (28.0%) partly received radiotherapy alone as a result
of their toxicity response. The proportion of total administered dose to planned dose was 90.9%
for chemotherapy and 99.3% for radiotherapy, which were comparable to those in previous studies
for LA-NSCLC patients without poor risk factors. Grade 3 leukopenia and neutropenia developed
in 14 patients (56.0%) and 10 patients (40.0%), respectively, but grade 4 toxicity was not encoun-
tered. Grade 3 pneumonitis and esophagitis were observed in 4 patients (16.0%) and 2 patients
(8.0%), respectively. The overall response rate was 60.0%. The median survival time was 22
months, and the 2-year survival rate was 50.3%. Daily low-dose cisplatin and concurrent thoracic
irradiation were well tolerated even by poor-risk patients with NSCLC, and showed a therapeutic
efficacy similar to that for good-risk patients.
KEYWORDS: non-small-cell lung cancer, concurrent chemoradiotherapy, low-dose cisplatin,
poor-risk factor
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0 1 2 3 4
Hematologicaltoxicity
Leukopenia 2 0 9 14 0
Neutropenia 2 4 9 10 0
Thrombocytopenia 3 13 7 2 0
Anemia 2 9 11 3 0
Non-hematologicaltoxicity
Esophagitis 14 8 1 2 0
Pneumonitis 19 2 0 4 0
Dermatitis 22 1 0 0 0
Nausea/vomiting 12 8 2 3 0
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